Chicago Atlantic Real Estate Finance, Inc. — 2022 Form 10-K
Business context and reporting period. The company is an externally managed commercial real estate finance REIT focused primarily on senior loans to state-licensed cannabis operators and property owners. Its fiscal year ended December 31, 2022. The company began operations in March 2021, so the 2021 comparison covers only the period from inception through year-end and is not directly comparable with the full 2022 year.
Financial and operating highlights
| Metric | 2022 | Comparison / year-end position |
|---|---|---|
| Interest income | $51.5 million | $11.1 million in the 2021 inception period |
| Net interest income | $48.9 million | $11.0 million in the 2021 inception period |
| Net income | $32.3 million; $1.83 basic and $1.82 diluted EPS | $9.5 million; $1.47 basic and diluted EPS in the 2021 inception period |
| Distributable earnings | $37.2 million; adjusted distributable earnings per share of $2.11 basic and $2.10 diluted | Non-GAAP measures; distributable earnings include certain accrued income not yet received in cash |
| Operating cash flow | $17.0 million | $6.7 million in the 2021 inception period |
| Investing cash flow | $(125.2) million | Primarily loan originations and fundings |
| Financing cash flow | $33.7 million | Included $58.0 million revolver borrowings, partly offset by dividends paid |
| Cash | $5.7 million | Down from $80.2 million at year-end 2021 |
| Debt and liquidity | $58.0 million drawn on a $92.5 million revolving facility; $34.5 million available | Company reported compliance with facility covenants at year-end |
| Assets, liabilities, equity | $343.3 million; $79.2 million; $264.0 million | Book value per share was approximately $14.86, versus $15.13 in 2021 |
| Loan portfolio | 22 loans; $343.0 million principal and $339.3 million carrying value before CECL reserve | Weighted-average estimated YTM IRR was 19.7%, versus 18.6% in 2021 |
| Credit-loss reserve | $3.94 million on funded loans, plus approximately $94,000 for unfunded commitments | Provision for expected credit losses was $3.89 million in 2022 |
Material changes versus the prior comparable period
- Interest income increased substantially as the company deployed capital raised through its IPO and follow-on share issuance, funded new loans, and benefited from higher Prime Rate levels. The weighted-average portfolio YTM IRR rose to 19.7% from 18.6%.
- The portfolio grew from $200.6 million of principal at year-end 2021 to $343.0 million at year-end 2022. Floating-rate loans rose to 83.1% of the portfolio from 53.2%.
- Interest expense increased to $2.6 million, reflecting $58.0 million of revolver borrowings, higher rates, and amortization of financing costs.
- The expected-credit-loss provision increased to $3.89 million from $148,000. Management attributed the increased reserve and weaker internal risk ratings mainly to macroeconomic reassessments and rising rates, rather than borrower-specific credit problems; it reported that loans continued to perform as expected.
- The company declared $2.10 per share in 2022 distributions, including a $0.29 special dividend. The fourth-quarter regular dividend of $0.47 and special dividend were paid in January 2023. The filing cautions that these payments do not indicate future dividend capacity.
Outlook, commentary, and key risks
- Outlook: Management intends to continue growing its cannabis-focused loan portfolio and expects to seek additional equity and/or debt financing. It also expects capital recycling through loan repayments and paydowns, and a shelf registration statement. The filing provides no specific earnings or dividend guidance.
- Subsequent events: In February 2023, the revolver maturity was extended to December 16, 2024, with a further one-year extension option subject to conditions. The company also raised approximately $6 million net in a registered direct offering in February 2023. During January–February 2023, it funded new and existing loans and received a loan paydown.
- Interest-rate exposure: Management estimated that a 100-basis-point change in Prime would change annual loan interest income by approximately $2.8 million and revolver interest expense by approximately $0.6 million, before other effects.
- Cannabis legal and enforcement risk: Cannabis remains illegal under U.S. federal law. Changes in federal enforcement, state laws, licensing, or banking access could impair borrowers, collections, collateral values, and the company’s ability to operate.
- Collateral and recovery risk: The company cannot take title to property while it is used for cannabis operations under its stated legal and listing constraints; licenses are generally not transferable, and the company has no liens on cannabis inventory. Foreclosure or sale may be delayed, restricted, or yield less than outstanding principal. Appraised collateral values are estimates and may not equal realizable recovery values.
- Portfolio and funding risk: The portfolio is concentrated in cannabis lending and a limited number of borrowers and jurisdictions. Higher borrowing costs, limited capital-market access, competition, borrower distress, and refinancing needs could pressure returns and liquidity. Approximately 18% of the portfolio was not fully collateralized by real estate, though secured by other permitted collateral; the filing also reports average real estate collateral coverage of 1.7x.
- Noncash income and REIT obligations: PIK interest and original issue discount can be recognized as income before cash is collected, while REIT distribution requirements may require cash distributions. PIK interest was $6.9 million in 2022. The company must also maintain REIT qualification and its Investment Company Act exemption.
- Management and controls: The company is externally managed and pays management, incentive, and reimbursable expenses; 2022 total payments to the Manager were approximately $9.7 million. Management reported that previously identified material weaknesses in internal controls were remediated and that controls were effective at year-end; the independent auditor did not attest to internal control effectiveness.
- Audit and contingencies: BDO issued an unqualified opinion on the consolidated financial statements. The company reported no material legal proceedings and no borrower payment defaults as of the filing date.
Important facts for investors to verify
- Whether loan performance, borrower liquidity, internal risk ratings, and the $3.94 million CECL reserve remain appropriate as rates and market conditions change.
- How much of reported earnings and distributable earnings reflects cash interest versus PIK, OID, and other accrued or contingent fees, and whether distributions are covered by recurring cash flow.
- Current revolver utilization, borrowing cost, covenant headroom, maturity-extension conditions, and access to additional financing.
- Borrower and geographic concentration, collateral valuations and coverage, and practical recovery options given cannabis-related legal, licensing, and transfer restrictions.
- Future dividends and the company’s ability to meet REIT distribution requirements without relying on new borrowing, equity issuance, or asset sales.
- Manager fee calculations, affiliate loan allocations and transactions, and continuing progress in internal-control procedures.